Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk
Company has changed auditors in a bid to comply with U.S. law and avoid a potential forced delisting from the Nasdaq Key Takeaways: BeiGene has switched auditors for its New…
RELATED ARTICLES
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG -
Everest reaches new heights on growing drug sales
1952.HK
